Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock

Abraham Ceesay, CEO and director of Rapport Therapeutics (RAPP), sold $143,272 worth of company common stock in two transactions on October 6 and 7, 2026. The stock traded at $30.65, down 5% from the previous week and 42% below its 52-week high of $52.93. Analysts rate the stock slightly undervalued, with price targets ranging from $50 to $80.

Ceesay disposed of 3,375 shares on October 6 at an average price of $32.0314 each. Two days later, he sold an additional 1,147 shares at an average of $30.66 per share. Both transactions were made following Rule 10b5-1 trading plans adopted by Ceesay in March 2026. Currently, he personally holds 452,245 shares through direct ownership and 81,729 shares indirectly via trusts.